Brought to you by 
Celgene to buy Gloucester for $340mm up front
19 Jun 2012
Executive Summary
Celgene will pay $340mm in cash up front and up to $300mm in regulatory earn-outs to acquire privately held cancer therapeutics developer Gloucester Pharmaceuticals.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com